European Vaccine Initiative (EVI)

European Vaccine Initiative (EVI) is a not-for-profit Product Development Partnership (PDP) that supports the development of safe, effective and affordable vaccines for global health through collaboration and coordination. EVI operates as an independent, science-driven organisation, leading innovative solutions in vaccines through research, development, capacity strengthening and advocacy. EVI works closely with partners and donors worldwide to move vaccines forward.
EVI´s portfolio and activities are diverse. Since its inception in 1998, EVI has collaborated in the development of more than 40 vaccine formulations against diseases like malaria, leishmaniasis, Zika virus and diarrhoeal diseases, 9 of which progressed into mid-stage clinical development. EVI is also supporting vaccine development through cross-cutting projects ranging from the development of non-animal approaches for vaccine quality control testing and assay harmonisation, to the establishment of a sustainable European vaccine infrastructure that can accelerate vaccine development across several disease areas, among many other projects and activities.

Kintampo Health Research Centre

Kintampo Health Research Centre is one of the leading research institutions in Ghana, established in 1994 as part of the Ghana Health Service Research and Development Division. KHRC has well-equipped clinical trial facilities, clinical laboratory with international quality-assurance systems, data management centre capable of processing/protecting large clinical datasets. Since 1995 KHRC has engaged community members to guarantee culturally acceptable research practices using consensus-building techniques in planning and implementation. With >60 scientific staff of various research disciplines, KHRC conducted clinical trials leading to high public health impact. KHRC is currently the coordinating institution for Malaria Vaccine Pilot Evaluation in Ghana. KHRC operates with support from generous donors, funding agencies, collaborators, Ghana Health Service and the Ministry of Health.

London School of Hygiene and Tropical Medicine

London School of Hygiene and Tropical Medicine is a world-leading centre for research and postgraduate education in public and global health. LSHTM delivers research-led educational programmes to future health leaders, managers and researchers across the world with 4,200 Master's and Doctoral students, 1,000 students each year on short-courses, and 70,000 using free online-courses. LSHTM staff have expertise in vaccine evaluation, including extensive experience in the design, conduct and analysis of case- control studies. LSHTM is already involved in MVPE, providing data management/statistical support.

Kenya Medical Research Institute (KEMRI)

Kenya Medical Research Institute (KEMRI) is a state corporation with the mission to improve human health and quality of life through research, capacity building, innovation and service delivery. The Centre for Global Health Research (CGHR) is located in Kisumu, western Kenya, with high burden of malaria/other infectious diseases and a high infant/under 5 child mortality. Since its inception (1984), CGHR performed ground-breaking research on epidemiology, surveillance, clinical trials, implementation research, qualitative research on infectious diseases of public health importance including malaria. KEMRI-CGHR has excellent capacity: well-trained staff, state-of-the-art laboratories, financial/administrative support systems, good information communication technology and data management systems.

African Research Collaboration for Health Limited Kenya

University of Oxford, Wellcome Trust and KEMRI formed the KEMRI-Wellcome Trust Research Programme (KWTRP) in 1989 with the vision/mission to deliver high quality research that is relevant to global health and to build local capacity for undertaking research. KWTRP’s research portfolio includes implementation science, epidemiology, clinical trials, molecular biology and social science. Vaccine development is one of five major research themes, with e.g. Phase II/III RTS,S vaccine trials performed in collaboration with KEMRI-CDC. KWTRP members serve on the Kenyan technical advisory group for vaccination policy for the MoH, and on numerous other policy interfaces. KWTRP established standardized enhanced clinical surveillance, in partnership with the MoH, and six hospitals are sentinels for MVIP evaluation.

College of Medicine, University of Malawi

University of Oxford, Wellcome Trust and KEMRI formed the KEMRI-Wellcome Trust Research Programme (KWTRP) in 1989 with the vision/mission to deliver high quality research that is relevant to global health and to build local capacity for undertaking research. KWTRP’s research portfolio includes implementation science, epidemiology, clinical trials, molecular biology and social science. Vaccine development is one of five major research themes, with e.g. Phase II/III RTS,S vaccine trials performed in collaboration with KEMRI-CDC. KWTRP members serve on the Kenyan technical advisory group for vaccination policy for the MoH, and on numerous other policy interfaces. KWTRP established standardized enhanced clinical surveillance, in partnership with the MoH, and six hospitals are sentinels for MVIP evaluation.College of Medicine, University of Malawi is the only medical college in Malawi with mandate to train health workers and generate research data for policy. COM collaborated with Malawi national health programs to become a center of excellence in training/research. COM is leading a research consortium on MVPE in eleven districts across Malawi. COM has all required facilities: training facilities, secure internet connection, robust Data Management and Biostatistics Unit, modern laboratories and research support center to manage research grants. Senior staff sits on several technical working groups where they influence both malaria and vaccine policy.

PATH

PATH is a global non-profit organization that works to accelerate health equity by bringing together public institutions, businesses, social enterprises, and investors to solve the world’s most pressing health challenges. PATH’s Center for Vaccine Innovation and Access accelerates the development and delivery of life-saving vaccines around the world and partners with countries in sub-Saharan African and Southeast Asia to advance and sustain immunization equity and vaccination coverage. PATH has two decades of experience in advancing various malaria vaccine candidates, including RTS,S, and is now partnering to support the pilot introductions of the vaccine.

This project is part of the
EDCTP2 Programme supported by the European Union (RIA2020S-3310 – MVPE-CC)